# Taysha Gene Therapies, Inc.: Form 8-K, filed Jun 2, 2026

- Company: [Taysha Gene Therapies, Inc.](/companies/tsha.md) (CIK 1806310)
- Form: 8-K
- Filed: 2026-06-02
- Accepted by EDGAR: Jun 2, 2026, 16:05 ET
- Period: 2026-06-01
- Accession: 0001193125-26-253478
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1806310/000119312526253478/d159199d8k.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1806310/000119312526253478/

## Items reported

- Item 5.07: Shareholder vote results

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1806310/000119312526253478/d159199d8k.htm

Filed Jun 2, 2026.
Source: SEC EDGAR, the filing index for accession 0001193125-26-253478. Last ingested by Listed: Nov 12, 2026, 18:00 ET. No prices; not investment advice.
